2000-05-01
A pilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix
Publication
Publication
Fertility and Sterility , Volume 73 - Issue 5 p. 1051- 1054
Objective: To study whether minimal interference in the process of selection of the single dominant follicle may serve as the basis for a simplified ovarian stimulation regimen for IVF. Design: Single-center randomized pilot study. Setting: Tertiary referral fertility center. Patient(s): Fifteen normo-ovulatory patients with a regular indication for IVF. Intervention(s): Ovarian stimulation for IVF was begun with 100 or 150 IU/d recombinant FSH starting on cycle day 5. From cycle day 8 or later, cotreatment was begun with 0.25 mg/d GnRH antagonist. No luteal support was provided. Main Outcome Measure(s): Total number of dominant follicles and characteristics of the endocrine cycle. Result(s): Multiple follicle development occurred in five of eight patients in the 100-IU group and in all seven women in the 150-IU group. Follicular phase and luteal phase lengths were normal, but the endocrine profile was abnormal. Conclusion(s): A fixed daily dose of 150 IU recombinant FSH starting in the midfollicular phase resulted in ongoing growth of a restricted number of dominant follicles and sufficient oocytes retrieved to lead to ET. A marked reduction in the total amount of gonadotropins administered compared with standard treatment was achieved. Withholding luteal support did not exclude pregnancies. (C)2000 by American Society for Reproductive Medicine.
Additional Metadata | |
---|---|
, , , | |
doi.org/10.1016/S0015-0282(00)00414-3, hdl.handle.net/1765/61562 | |
Fertility and Sterility | |
Organisation | Department of Gynaecology & Obstetrics |
de Jong, D., Macklon, N., & Fauser, B. (2000). A pilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertility and Sterility, 73(5), 1051–1054. doi:10.1016/S0015-0282(00)00414-3 |